Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 47, Issue 7, 2001, Pages S38-S44

  Sakalová, Adriena ^a   Bock, Paul R ^c   Dedík, Ladislav ^b   Hanisch, Jürgen ^c   Schiess, Wilfried ^d   Gažová, Slávka ^a   Chabroňová, Irena ^a   Holomanova, Dagmar ^a   Mistrík, Martin ^a   Hrubiško, Mikuläš ^a  

^a University of Brastislava   (Slovakia)

^b SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

^c Ifag Basle   (Switzerland)

^d Clinical Research   (Germany)

Author keywords

Additive treatment; Multiple myeloma; Oral enzyme preparation; Retrolective cohort study; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CHYMOTRYPSIN; CYCLOPHOSPHAMIDE; LOMUSTINE; MELPHALAN; METHYLPREDNISOLONE; PAPAIN; PREDNISONE; TRYPSIN; VINCRISTINE; WOBENZYM;

ADULT; AGED; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME THERAPY; EVALUATION; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; SLOVAKIA; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHYMOTRYPSIN; COHORT STUDIES; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DRUG COMBINATIONS; ENDOPEPTIDASES; FEMALE; HUMANS; LOMUSTINE; MALE; MELPHALAN; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE MYELOMA; PAPAIN; PREDNISONE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRYPSIN; VINCRISTINE;

EID: 0034919720     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. The treatment of multiple myeloma
2. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials
3. Standard treatment of multiple myeloma
4. Viewpoint on the impact of interferon in the treatment of multiple myeloma: Benefit for a small proportion of patients?
5. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
6. Combination chemotherapy, glucocorticoids, and interferon alpha in the treatment of multiple myeloma: A Southwest Oncology Group study
7. Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis
8. Proteolytic enzymes modulate the adhesion molecule CD44 on malignant cells in vitro
9. Transforming growth factor-beta and p-21: Multiple molecular targets of decorin-mediated suppression of neoplastic growth
10. Concentrations of soluble tumor necrosis factor receptors, beta2-microglobulin, IL-6 and TNF in serum of multiple myeloma patients after chemotherapy and after combined enzyme-chemotherapy
11. Interferon production in whole blood cultures from volunteers and rheumatoid arthritis patients after medication with oral enzymes
12. Blockade of metastasis formation by CD44-receptor globulin
13. The efficacy of trypsin: Chymotrypsin preparation in the reduction of oxidative damage during burn injury
14. Stimulation of reactive oxygen species production and cytotoxicity in human neutrophils in vitro and after oral administration of a polyenzyme preparation
15. Bromelain, from pineapple stems, proteolytically blocks activation of extracellular regulated kinase-2 in T cells
16. Progression markers in serum of patients with multiple myeloma
17. Recent immunological approaches and therapy of multiple myeloma
18. Comparative epidemiological study in patients with rheumatic diseases illustrated in an example of a treatment with non-steroidal anti-inflammatory drugs versus an oral enzyme combination
19. Effective treatment of advanced multiple myeloma refractory to alkylating agents
20. Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: What is the best combination for myeloma prognosis?
21. Cellular and molecular genetic features of myeloma and related disorders
22. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
23. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial
24. The role of serpin superfamily members in cancer